Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Lymphoma
- Lymphoma Non-Hodgkin
- Myelodysplasia
- Myelofibrosis
- Myeloproliferative Disorder
- Plasma Cell Disorder
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03480360
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Kenneth Meehan, MD Dartmouth-Hitchcock Medical Center
Get Well Soon